Additionally, they found that JQ1 also promotes cellular senescence through activation of cell cycle kinase inhibitors and inhibition of E2F1 activity, an effect that was also observed in vivo [47]. The preclinical data in these studies supports the pursuit of testing BET inhibitors as molecular targeted therapeutic options for patients with MYC-driven medulloblastoma. This evidence concerns the gene DNER and medulloblastoma.